Diltiazem and Buprenorphine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jul 2, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Buprenorphine
Diltiazem
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
You're taking buprenorphine (a pain or opioid-dependence medicine) along with diltiazem (a heart and blood pressure medicine). Diltiazem slows down the liver enzyme that normally breaks buprenorphine down. That means more buprenorphine can build up in your body than expected.
With higher levels, opioid effects can be stronger or last longer. The main things to watch for are heavy drowsiness, confusion, and slow or shallow breathing. This is manageable. Your care team may adjust your buprenorphine dose and keep a closer eye on you. Keep taking both exactly as prescribed, and let your pharmacist or doctor know if you feel unusually sleepy or notice slowed breathing.
Effect: Diltiazem, a moderate CYP3A4 inhibitor, reduces CYP3A4-mediated metabolism of buprenorphine, increasing buprenorphine exposure and the risk of opioid-related adverse events (sedation, respiratory depression). Direction: increased buprenorphine effect.
- Onset: unspecified; evidence: probable.
- Severity: major.
- Management: If initiating diltiazem, consider reducing the buprenorphine dose until stable, monitoring frequently for sedation/respiratory depression. On diltiazem discontinuation, anticipate the need to increase buprenorphine and monitor for withdrawal.
- For long-acting/subQ formulations, use products permitting precise titration; monitor for over-medication or inadequate levels as applicable.
What happens
Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events
Interaction Deep Dive
Taking buprenorphine together with a CYP3A4 inhibitor can raise buprenorphine plasma levels, which may result in extended opioid effects such as respiratory depression. When a patient on buprenorphine needs a CYP3A4 inhibitor, it may be appropriate to lower the buprenorphine dose until drug effects stabilize, with frequent observation for sedation and respiratory depression. Conversely, upon stopping a CYP3A4 inhibitor in someone maintained on buprenorphine, an increase in the buprenorphine dose may be warranted until stable effects are reached, along with monitoring for opioid withdrawal signs2. Should dose adjustment prove impossible once the CYP3A4 inhibitor is gone, the patient should be switched back to a buprenorphine formulation that allows finer dose titration. For patients being converted from transmucosal buprenorphine used alongside CYP3A4 inhibitors, verify that the plasma buprenorphine level achieved with subQ buprenorphine is sufficient. For those already receiving subQ buprenorphine who then require a CYP3A4 inhibitor, watch for indications of over-medication. If buprenorphine toxicity or overdose signs and symptoms develop and the co-administered drug cannot be lowered or stopped, decrease the buprenorphine dose. When the available doses do not allow the target dose to be reached, stop the treatment and manage the patient with a buprenorphine formulation that supports more precise dose adjustments 1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of buprenorphine
How to manage this interaction
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring.
- Your team may reduce your buprenorphine dose while you are on diltiazem and watch you more closely for sedation and slowed breathing.
- If diltiazem is later stopped, they may raise your buprenorphine dose again and watch for withdrawal symptoms.
- If you are on a long-acting or injectable form, your team may use a version that allows more precise dose changes.
Call your pharmacist or prescriber if you feel very drowsy, confused, or notice slow or shallow breathing.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) The impact of concurrently administered CYP3A4 inhibitors on buprenorphine exposure in individuals receiving subQ buprenorphine has not been investigated; nevertheless, these interactions have been demonstrated in trials employing transmucosal buprenorphine. The effects of buprenorphine may vary according to the route of administration 1.
Common questions
Can I take Diltiazem and Buprenorphine together?
Diltiazem can raise buprenorphine levels and increase the risk of excess sedation and slowed breathing; keep taking both as prescribed but have your care team adjust the dose and monitor you, and report any heavy drowsiness or slow breathing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Diltiazem and Buprenorphine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Diltiazem and Buprenorphine interaction managed?
Keep taking both medicines as prescribed unless your care team tells you otherwise. This combination is manageable with the right adjustments and monitoring. Your team may reduce your buprenorphine dose while you are on diltiazem and watch you more closely for sedation and slowed breathing. If diltiazem is later stopped, they may raise your buprenorphine dose again and watch for withdrawal symptom… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "probable". Good supporting evidence, though not definitively proven.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Diltiazem or Buprenorphine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (2)
- Product Information: BRIXADI(TM) subcutaneous extended-release injection, buprenorphine subcutaneous extended-release injection. Braeburn Inc (per FDA), Plymouth Meeting, PA, 2023. DailyMed
- Product Information: ZUBSOLV(R) sublingual tablets, buprenorphine naloxone sublingual tablets. Orexo US Inc (per FDA), Morristown, NJ, 2023. DailyMed
Keep reading about Buprenorphine
Keep reading about Diltiazem
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist